
For US payers, pegfilgrastim is a less-expensive choice than daily filgrastim for reducing the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
For US payers, pegfilgrastim is a less-expensive choice than daily filgrastim for reducing the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
Published: June 12th 2025 | Updated: June 16th 2025
Published: June 10th 2025 | Updated: June 12th 2025
Published: June 2nd 2025 | Updated: June 11th 2025
Published: June 3rd 2025 | Updated: June 11th 2025
Published: May 30th 2025 | Updated: June 5th 2025
Published: April 18th 2025 | Updated: April 21st 2025